Johnson & Johnson (JNJ) Becomes Sector Gamma AS's 6th-Largest Holding

Johnson & Johnson (NYSE:JNJ) is among the best stocks to buy now according to AI. According to the recent disclosure with the Securities and Exchange Commission (SEC), Sector Gamma AS has increased its position in Johnson & Johnson (NYSE:JNJ) by 25.6% in the first quarter. The firm now owns 98,000 shares of the company’s stock, including the addition of 20,000 shares. With a stake worth $16.25 million, the consumer healthcare giant ranks as Sector Gamma AS’s sixth-largest holding.

Many analysts believe that the story of Johnson & Johnson (NYSE:JNJ) is far from over. Just recently, the company’s revenue and EPS surpassed Wall Street’s expectations by a significant margin. If its “outdated” superstar Stelara is weakening, the oncology franchise is gaining momentum. So, much of the decline has been more than compensated for. And that’s what is so special about the company.

Much of the hope surrounds Erleada, which is becoming the definitive standard in prostate cancer treatment, achieving $908 million in sales. This 17.8% quarter-over-quarter increase signals one thing: it’s just getting started.

Johnson & Johnson (NYSE:JNJ), headquartered in New Jersey, offers healthcare products worldwide. Founded in 1886, the company operates in two main segments: Innovative Medicine and MedTech. With a commitment to care for the world, the healthcare powerhouse distributes its products to wholesalers, hospitals, and retailers.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.